Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Immutep Ltd ( (AU:IMM) ).
Immutep Ltd has announced the issuance of 4,055,555 fully paid ordinary shares, which will be quoted on the Australian Securities Exchange (ASX) starting October 1, 2025. This move is part of the company’s strategy to enhance its capital structure and potentially strengthen its market position, offering stakeholders an opportunity to invest in its growth and development.
The most recent analyst rating on (AU:IMM) stock is a Buy with a A$1.20 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Ltd operates in the biotechnology industry, focusing on developing immunotherapy treatments. The company is known for its work on innovative therapies aimed at modulating the immune system to treat cancer and autoimmune diseases.
Average Trading Volume: 2,438,246
Technical Sentiment Signal: Sell
Current Market Cap: A$381.6M
For detailed information about IMM stock, go to TipRanks’ Stock Analysis page.